Restoration of Foveal Bulge after Resolution of Diabetic Macular Edema with Coexisting Serous Retinal Detachment

Hu, Yijun; Wu, Qiaowei; Huang, Manqing; Peng, Qingsheng; Zhong, Pingting; Zeng, Xiaomin; Xiao, Yu; Liu, Cong; Fang, Ying; Li, Tao; Yu, Honghua; Yang, Xiaohong

doi:10.1155/2020/9705786

Cited by 4 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same issue also occurred in patients with macular edema secondary to branch retinal vein occlusion (BRVO-ME), DME with serous retinal detachment (SRD-DME), and rhegmatogenous retinal detachment (10)(11)(12). In these patients, foveal bulge (FB) can serve as a biomarker of better visual recovery after retinal reattachment or complete edema resolution (10)(11)(12). Therefore, we propose that FB has an important impact on the visual recovery after the resolution of DME.…”

Section: Introductionmentioning

confidence: 89%

“…However, the visual prognosis is still unsatisfactory in some patients with resolved DME and complete integrity of EZ at the fovea. The same issue also occurred in patients with macular edema secondary to branch retinal vein occlusion (BRVO-ME), DME with serous retinal detachment (SRD-DME), and rhegmatogenous retinal detachment (10)(11)(12). In these patients, foveal bulge (FB) can serve as a biomarker of better visual recovery after retinal reattachment or complete edema resolution (10)(11)(12).…”

Section: Introductionmentioning

confidence: 92%

“…Eyes with DME affecting the central fovea at baseline and resolved DME with complete integrity of EZ at 6 months were included. We included eyes that were untreated or received previous anti-vascular endothelial growth factor (VEGF) or pan-retinal photocoagulation (PRP) at least 6 months ago and eyes with the central foveal thickness (CFT) over 275 µm and BCVA between 0.3 and 1.0 logarithm of the minimal angle of resolution (LogMAR) (20/200-20/40) at baseline (12,19). Eyes with macular edema secondary to other causes, such as retinal artery/vein occlusion, age-related macular degeneration, and polypoidal choroidal vasculopathy, eyes with macular ischemia, glaucoma or IOP > 21 mmHg, a history of macular grid photocoagulation or vitrectomy, refractive error over 6 diopters (D), severe cataracts, or previously treated with PRP or intravitreal or periocular injection <6 months were excluded (12,17).…”

Section: Subjectsmentioning

confidence: 99%

“…All included eyes received a loading dose of 3 monthly consecutive 0.5-mg intravitreal injections of ranibizumab (IVR) treatment. After the loading treatment, patients were followed on monthly basis and received 1 IVR injection if they met any of the following criteria: (A) CFT increases by ≥ 100 µm; (B) BCVA decreases by ≥ 0.1 LogMAR; or (C) the decrease of BCVA attributed to newly formed SRD or intraretinal cyst, based on the surgeons; or (D) the decrease of BCVA due to enlargement of previous SRD or intraretinal cyst, based on the surgeons (9,12,17). IVR injection was suspended if either of the following criteria was met: (A) BCVA ≤ 0.0 LogMAR (20/20) observed at the two last consecutive follow-ups; or (B) stable BCVA over three consecutive follow-ups that include the current follow-up evaluation, specifically no improvement of BCVA due to IVR injections at the two last consecutive follow-ups (9,12,17).…”

Section: Treatmentmentioning

confidence: 99%

“…Therefore, these DME types can be further classified into SRD and non-SRD (i.e., DRT and CME) categories according to their different pathogenesis (17). Our previous study has demonstrated the association between the restoration of FB and severity of SRD in eyes with resolved SRD-DME (12), but the effect of non-SRD on the restoration of FB is still unknown.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Factors Associated With the Presence of Foveal Bulge in Eyes With Resolved Diabetic Macular Edema

Lin

et al. 2022

Front. Med.

Self Cite

View full text Add to dashboard Cite

Purpose: To evaluate factors associated with the presence of foveal bulge (FB) in resolved diabetic macular edema (DME) eyes.Methods: A total of 165 eyes with complete integrity of ellipsoid zone (EZ) at the fovea and resolved DME were divided into two groups according to the presence of FB at 6 months after intravitreal injection of ranibizumab treatment. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), outer nuclear layer (ONL) thickness, height of serous retinal detachment (SRD) and non-SRD, and inner segment (IS) and outer segment (OS) lengths of the two groups were measured and compared at baseline and each follow-up. The correlations between the presence of FB and pre- and post-treatment factors were determined by logistic regression analysis.Results: At baseline, BCVA was significantly better, and CFT and incidence and height of SRD were significantly lower in the FB (+) group (all P < 0.05). At 6 months, FB was present in 65 (39.39%) eyes. Post-treatment BCVA was significantly better and OS length was significantly longer in the FB (+) group at 6 months (all P < 0.05). Multivariate analysis identified younger age, better BCVA, and lower CFT before treatment as significant predictors of the existence of FB at 6 months (all P < 0.05). At 6 months, better BCVA and longer OS length were significantly correlated with the existence of FB (all P < 0.05).Conclusions: Factors associated with the presence of FB after the resolution of DME include younger age, better baseline BCVA and lower baseline CFT, and better post-treatment BCVA and longer post-treatment OS length.

show abstract

Section: Introductionmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 92%

Section: Subjectsmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Factors Associated With the Presence of Foveal Bulge in Eyes With Resolved Diabetic Macular Edema

Lin

et al. 2022

Front. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review

Yuen¹,

Tan²,

Gan³

et al. 2022

OPTH

View full text Add to dashboard Cite

Purpose To evaluate the visual outcomes and safety profile of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in the treatment of diabetic macular edema (DME) in real-world studies in Asian countries. Methods A systematic review of electronic literature databases (Embase, Medline, and the Cochrane Library from January 1, 2010, to March 16, 2021) was conducted to identify observational studies that reported clinical and safety outcomes of anti-VEGF treatments for DME in Asia. We analyzed baseline patient characteristics, treatment patterns, mean number of injections, best-corrected visual acuity (BCVA), retinal thickness, and safety outcomes. Results Seventy-one studies were included in this review. Most studies reported treatment of DME with ranibizumab (n = 33), followed by aflibercept (n = 13), bevacizumab (n = 28), and conbercept (n = 9). At 12 months, the cumulative mean number of injections for ranibizumab, aflibercept, and conbercept was 5.2, 4.6, and 6, respectively. At the 12-month follow-up, the cumulative mean BCVA gain was 6.8 letters (ranibizumab), 4.6 letters (aflibercept), 4.9 letters (bevacizumab), and 8.3 letters (conbercept). The cumulative mean reduction in retinal thickness at 12 months was 116.9 μm (ranibizumab), 105.9 μm (aflibercept), 81.7 μm (bevacizumab), and 135.2 μm (conbercept). A strong positive correlation (r = 0.78) was observed between mean number of injections and change in BCVA at 12 months. A moderate positive correlation (r = 0.54) was observed between mean number of injections and mean reduction in retinal thickness at 12 months. A weak positive correlation was observed between baseline retinal thickness and visual acuity at 12 months. Baseline BCVA and mean number of injections were predictors of BCVA at 12 months. Conclusion All anti-VEGFs were effective in the treatment of DME in Asia. The data suggest that a greater number of anti-VEGF injections was associated with better improvement in BCVA and moderate reduction in retinal thickness at the 1-year follow-up.

show abstract

Predictors of vision following ranibizumab injection for age-related macular degeneration

Moussa

Sayed

2021

Delta Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose The aim of this study was to investigate the optical coherence tomography (OCT) parameters that can predict the vision of patients with exudative age-related macular degeneration (AMD) 1 month following intravitreal ranibizumab injection. Patients and methods This is a prospective consecutive case-series study that was conducted on 20 eyes of 18 consecutive patients who received intravitreal ranibizumab injection for exudative AMD. A spectral-domain OCT imaging was done just before and 1 month following the injection. The main outcome measures were the correlations between the postinjection vision and the preinjection OCT parameters. Results A significant reduction was noted in retinal volume at the 3 and 5-mm central circles. The reduction in retinal thickness was statistically significant, while the reduction in other OCT parameters was insignificant. There was a strong correlation between postinjection vision and each of the following: foveal volume at 1 mm, full retinal thickness at the fovea, and retinal pigment epithelium elevation at the fovea (r>0.7, P<0.05). Multivariate analysis showed that the foveal volume (r 2=0.538) was the most important predictor factor for visual acuity, 1 month following ranibizumab injection. Conclusions Foveal volume is the most important factor for vision prediction and can be used as an early visual predictor 1 month following ranibizumab injection in patients with AMD.

show abstract

Restoration of Foveal Bulge after Resolution of Diabetic Macular Edema with Coexisting Serous Retinal Detachment

Cited by 4 publications

References 33 publications

Factors Associated With the Presence of Foveal Bulge in Eyes With Resolved Diabetic Macular Edema

Factors Associated With the Presence of Foveal Bulge in Eyes With Resolved Diabetic Macular Edema

Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review

Predictors of vision following ranibizumab injection for age-related macular degeneration

Contact Info

Product

Resources

About